Cumberland Pharmaceuticals Inc (NAS:CPIX)
$ 6.75 +0.75 (+12.5%) Market Cap: 101.14 Mil Enterprise Value: 99.86 Mil PE Ratio: 0 PB Ratio: 4.67 GF Score: 32/100

Q3 2025 Cumberland Pharmaceuticals Inc Earnings Call Transcript

Nov 4, 2025 / 09:30 PM GMT
Release Date Price: $2.66 (-3.62%)

Key Points

Positve
  • Cumberland Pharmaceuticals Inc (CPIX) announced a new addition to their commercial product portfolio with the joint commercialization of Talesia, an FDA-approved treatment for Helicobacter pylori infections.
  • The company reported a 12% year-to-date revenue growth over the same period last year, with total revenues of $30.9 million for the first nine months of 2025.
  • CPIX's portfolio of FDA-approved brands delivered combined revenues of $8.3 million during the third quarter.
  • The company has reduced its total debt by $10 million since the end of 2024, improving its financial position.
  • CPIX continues to generate positive cash flow from operations, which increased to nearly $5 million through September 2025.
Negative
  • Third-quarter sales were impacted by a delay in some Crystallos and Caldeor shipments.
  • The company reported an adjusted loss of $0.8 million or $0.06 per share for the third quarter.
  • CPIX faces increased substitution of its Crystallos product by pharmacies in favor of generic alternatives, impacting sales.
  • Total operating expenses for the third quarter were $10.3 million, contributing to a net loss for the quarter.
  • The company continues to face challenges from generic competition, particularly affecting its Crystallos product.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CPIX.OQ - Cumberland Pharmaceuticals Inc
Q3 2025 Cumberland Pharmaceuticals Inc Earnings Call
Nov 04, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Cumberland Pharmaceuticals 3rd quarter 2025 Financial Report and Company update.

This call is being recorded at the company's request and will be archived on its website for one year from today's date.

I would now like to turn it over to Emily Kent from the Dalton Agency who handles Cumberland's communications. Emily, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello, everyone, and thank you for joining us today.

This afternoon, Cumberland issued a press release announcing its 3rd
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot